Compact Human Il-1 Receptor Agonist Recombinant Protein Lyophilized - Today Only [TpFBSQfa]

High-Purity Human IL-1 Receptor Agonist Recombinant Protein

Introducing our Human IL-1 Receptor Agonist Recombinant Protein, a premium product designed for research and clinical applications. This lyophilized protein, produced through recombinant technology in E. coli, offers exceptional purity and reliability. With a purity of over 98% as verified by SDS-PAGE gel and HPLC analyses, this protein is a valuable tool for researchers seeking high-quality, consistent results.

Product Specifications and Features

Our Human IL-1 Receptor Agonist Recombinant Protein boasts a range of impressive specifications. It is sourced from E. coli, ensuring a consistent and reproducible product. The protein is buffered to maintain stability and purity, with an endotoxin level of less than 0.1 ng per μg (1EU/μg), making it suitable for sensitive applications. Key features include:

• Purity: Greater than 98% by SDS-PAGE gel and HPLC analyses.
• Endotoxin Level: Less than 0.1 ng per μg (1EU/μg).

Applications and Benefits

This Human IL-1 Receptor Agonist Recombinant Protein is a versatile tool for various research and clinical studies. Its application extends to the treatment of conditions such as sepsis, cachexia, rheumatoid arthritis, chronic myelogenous leukemia, asthma, psoriasis, and inflammatory bowel disease. By competitively blocking the binding of IL-1α and IL-1β to their respective receptors, this protein offers a promising therapeutic approach. The benefits of using this product include:

• Enhanced Research Outcomes: The high purity and specificity of this protein ensure reliable and consistent results.
• Wide Application Range: Suitable for a variety of research and clinical applications, making it a valuable asset to any laboratory or healthcare setting.